**Proteins** 



# **Product** Data Sheet

# EGFR Protein, Human (621a.a, CHO, His)

Cat. No.: HY-P7340

Synonyms: rHuEGFR, His; ERBB; ERBB1; HER1

Species: Human Source: СНО

Accession: P00533 (L25-S645)

Gene ID: 1956

Molecular Weight: 95-115 kDa

### **PROPERTIES**

LEEKKVCQGT SNKLTQLGTF EDHFLSLQRM FNNCEVVLGN LEITYVQRNY DLSFLKTIQE VAGYVLIALN TVERIPLENL QIIRGMMYYE NSYALAVLSN YDANKTGLKE LPMRNLQEIL HGAVRFSNNP ALCNVESIQW RDIVSSDFLS NMSMDFQNHL GSCQKCDPSC PNGSCWGAGE ENCQKLTKII CAQQCSGRCR GKSPSDCCHN QCAAGCTGPR ESDCLVCRKF RDEATCKDTC PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVVTDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The EDGO is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/mL can bind Anti-EGFR antibody, the EDGO fhuman EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized powder.  Formulation Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH20. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).  Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is					
LEITYVQRNY DLSFLKTIQE VAGYVLIALN TVERIPLENL QIIRGNMYE NSYALAVLSN YDANKTGLKE LPMRNLQEIL HGAVRFSNNP ALCNVESIQW RDIVSSDFLS NMSMDFQNHL GSCQKCDPSC PNGSCWGAGE ENCQKLTKII CAQQCSGRCR GKSPSDCCHN QCAAGCTGPR ESDCLVCRKF RDEATCKDTC PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVVTDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTG RPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH	AA Sequence		6 N K I T O I 6 T F	5 D H 5 L 6 L 6 D M	5 N N O 5 N N I O N
Q       R G N M Y Y E   N S Y A L A V L S N   Y D A N K T G L KE   L P M R N L Q E   L   H G A V R F S N N P   A L C N V E S I Q W   R D I V S S D F L S   N M S M D F Q N H L   G S C Q K C D P S C P N G S C W G A G E   E N C Q K L T K I I   C A Q Q C S G R C R G K S P S D C C H N   Q C A A G C T G P R   E S D C L V C R K F   R D E A T C K D T C P P L M L Y N P T T   Y Q M D V N P E G K   Y S F G A T C V K   C P R N Y V V T D H   G S C V R A C G A D   S Y E M E E D G V R   K C K K C E G P C R   K V C N G I G I G E F K D S L S I N A T   N I K H F K N C T S   I S G D L H I L P V   A F R G D S F T H T P P L D P Q E L D I   L K T V K E I T G F   L L I Q A W P E N R   T D L H A F E N L E   I R G R T K Q H G   Q F S L A V V S L N   I T S L G L R S L K   E I S D G D V I I S   G N K N L C Y A N T   I N W K K L F G T S   G Q K T K I I S N R   G E N S C K A T G Q V C H A L C S P E G   C W G P E P R D C V   S C R N V S R G R E   C V D K C N L L E G   E P R E F V E N S   C I Q C H P E C L P   Q A M N I T C T G R   G P D N C I Q C A H Y I D G P H C V K T   C P A G V M G E N N   T L V W K Y A D A G   H V C H L C H P N C   T Y G C T G P G L E   G C P T N G P K I P   S H H H H H H   H   H   H   H   H   H					
HGAVRFSNNP ALCNVESIQW RDIVSSDFLS NMSMDFQNHL GSCQKCDPSC PNGSCWGAGE ENCQKLTKII CAQQCSGRCR GKSPSDCCHN QCAAGCTGPR ESDCLVCRKF RDEATCKDTC PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVVTDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED50 is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/mI can bind Anti- EGFR antibody, the ED50 of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).					
GSCQKCDPSC PNGSCWGAGE ENCQKLTKII CAQQCSGRCR GKSPSDCCHN QCAAGCTGPR ESDCLVCRKF RDEATCKDTC PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVYDDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The EDSO is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/mL can bind Anti-EGFR antibody, the EDSO of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  *1 tis not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		=			•
GKSPSDCCHN QCAAGCTGPR ESDCLVCRKF RDEATCKDTC PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVVTDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized powder.  Formulation Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level <1 EU/µg, determined by LAL method.  Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).			•		•
PPLMLYNPTT YQMDVNPEGK YSFGATCVKK CPRNYVVTDH GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKHIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/ml can bind Anti-EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level <1 EU/µg, determined by LAL method.  Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		_		-	
GSCVRACGAD SYEMEEDGVR KCKKCEGPCR KVCNGIGIGE FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/ml can bind Anti-EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized powder.  Formulation Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level <1 EU/µg, determined by LAL method.  Reconstitution It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).					
FKDSLSINAT NIKHFKNCTS ISGDLHILPV AFRGDSFTHT PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 µg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 µg/mI can bind Anti-EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10 <sup>A</sup> 4 units/mg.  Appearance Lyophilized from a 0.2 µm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  Reconsititution  It is not recommended to reconstitute to a concentration less than 100 µg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).					
PPLDPQELDI LKTVKEITGF LLIQAWPENR TDLHAFENLE IIRGRTKQHG QFSLAVVSLN ITSLGLRSLK EISDGDVIIS GNKNLCYANT INWKKLFGTS GQKTKIISNR GENSCKATGQ VCHALCSPEG CWGPEPRDCV SCRNVSRGRE CVDKCNLLEG EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		GSCVRACGAD	SYEMEEDGVR	KCKKCEGPCR	KVCNGIGIGE
I I R G R T K Q H G Q F S L A V V S L N I T S L G L R S L K E I S D G D V I I S G N K N L C Y A N T I N W K K L F G T S G Q K T K I I S N R G E N S C K A T G Q V C H A L C S P E G C W G P E P R D C V S C R N V S R G R E C V D K C N L L E G E P R E F V E N S E C I Q C H P E C L P Q A M N I T C T G R G P D N C I Q C A H Y I D G P H C V K T C P A G V M G E N N T L V W K Y A D A G H V C H L C H P N C T Y G C T G P G L E G C P T N G P K I P S H H H H H H  Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10 <sup>A</sup> 4 units/mg.  Appearance  Lyophilized powder.  Formulation  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		FKDSLSINAT	NIKHFKNCTS	ISGDLHILPV	AFRGDSFTHT
G N K N L C Y A N T I N W K K L F G T S G Q K T K I I S N R G E N S C K A T G Q V C H A L C S P E G C W G P E P R D C V S C R N V S R G R E C V D K C N L L E G E P R E F V E N S E C I Q C H P E C L P Q A M N I T C T G R G P D N C I Q C A H Y I D G P H C V K T C P A G V M G E N N T L V W K Y A D A G H V C H L C H P N C T Y G C T G P G L E G C P T N G P K I P S H H H H H H   Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10 <sup>A</sup> 4 units/mg.  Appearance  Lyophilized powder.  Formulation  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  41 EU/μg, determined by LAL method.  Reconsititution  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		PPLDPQELDI	LKTVKEITGF	LLIQAWPENR	TDLHAFENLE
V C H A L C S P E G C W G P E P R D C V S C R N V S R G R E C V D K C N L L E G E P R E F V E N S E C I Q C H P E C L P Q A M N I T C T G R G P D N C I Q C A H Y I D G P H C V K T C P A G V M G E N N T L V W K Y A D A G H V C H L C H P N C T Y G C T G P G L E G C P T N G P K I P S H H H H H H   Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance  Lyophilized powder.  Formulation  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  *1 EU/μg, determined by LAL method.  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		IIRGRTKQHG	QFSLAVVSLN	ITSLGLRSLK	EISDGDVIIS
EPREFVENSE CIQCHPECLP QAMNITCTGR GPDNCIQCAH YIDGPHCVKT CPAGVMGENN TLVWKYADAG HVCHLCHPNC TYGCTGPGLE GCPTNGPKIP SHHHHHH  Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10 <sup>λ</sup> 4 units/mg.  Appearance Lyophilized powder.  Formulation Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  Al EU/μg, determined by LAL method.  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		GNKNLCYANT	INWKKLFGTS	GQKTKIISNR	GENSCKATGQ
Y I D G P H C V K T C P A G V M G E N N T L V W K Y A D A G H V C H L C H P N C T Y G C T G P G L E G C P T N G P K I P S H H H H H H  Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance  Lyophilized powder.  Formulation  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  Al EU/μg, determined by LAL method.  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		VCHALCSPEG	CWGPEPRDCV	SCRNVSRGRE	CVDKCNLLEG
Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance  Lyophilized powder.  Formulation  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Endotoxin Level  Al EU/μg, determined by LAL method.  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		EPREFVENSE	CIQCHPECLP	QAMNITCTGR	GPDNCIQCAH
Biological Activity  1. The ED <sub>50</sub> is <1 μg/mL as measured by 3T3 cells. 2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED <sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Appearance  Lyophilized powder.  Endotoxin Level  41 EU/μg, determined by LAL method.  Reconsititution  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		YIDGPHCVKT	$C\;P\;A\;G\;V\;M\;G\;E\;N\;N$	TLVWKYADAG	HVCHLCHPNC
<ul> <li>2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED<sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10<sup>4</sup> units/mg.</li> <li>Appearance Lyophilized powder.</li> <li>Formulation Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.</li> <li>Endotoxin Level </li> <li>Reconsititution It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH<sub>2</sub>O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).</li> </ul>		TYGCTGPGLE	GCPTNGPKIP	SHHHHHH	
<ul> <li>2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED<sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10<sup>4</sup> units/mg.</li> <li>Appearance Lyophilized powder.</li> <li>Formulation Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.</li> <li>Endotoxin Level </li> <li>Reconsititution It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH<sub>2</sub>O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).</li> </ul>					
<ul> <li>2. Measured by its binding ability in a functional ELISA. Immobilized EGFR at 1 μg/ml can bind Anti- EGFR antibody, the ED<sub>50</sub> of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10<sup>4</sup> units/mg.</li> <li>Appearance Lyophilized powder.</li> <li>Formulation Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.</li> <li>Endotoxin Level </li> <li>Reconsititution It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH<sub>2</sub>O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).</li> </ul>	District Astron	1 Th. FD. '1/			
of human EGFR protein is 13.1 ng/mL, corresponding to a specific activity is 7.63×10^4 units/mg.  Lyophilized powder.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.  Lyophilized from a 0.2 μm filtered	Biological Activity	• • • • • •		Immobilized ECED at 1 us/	ral can hind Anti FCFD antibady the FD
Appearance       Lyophilized powder.         Formulation       Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.         Endotoxin Level       <1 EU/μg, determined by LAL method.         Reconsititution       It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		,			2.
Formulation       Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.         Endotoxin Level       <1 EU/μg, determined by LAL method.         Reconsititution       It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).		of numan EGFR protein is	13.1 ng/mL, corresponding	to a specific activity is 1.63×.	10^4 units/mg.
Formulation       Lyophilized from a 0.2 μm filtered solution of PBS or 20 mM PB, 150 mM NaCl, pH 7.4.         Endotoxin Level       <1 EU/μg, determined by LAL method.         Reconsititution       It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Annorrance	Luanhilizad naudar			
Endotoxin Level <1 EU/μg, determined by LAL method.  Reconsititution  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Арреагансе	Lyopiiiizea powaei.			
Endotoxin Level <1 EU/μg, determined by LAL method.  Reconsititution  It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Formulation	Lyanhilizad from a 0.2 um	filtered colution of DDC or 2	O mM DP 150 mM NaCl nH :	7.4
Reconsititution It is not recommended to reconstitute to a concentration less than 100 $\mu$ g/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Formulation	Lyopiiiiized iroiii a 0.2 µiii	intered solution of FB3 of 2	.0 IIIM FB, 130 IIIM NaCi, pii	1.4.
Reconsititution It is not recommended to reconstitute to a concentration less than 100 $\mu$ g/mL in ddH <sub>2</sub> O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Endotovin Level	<1 FII/ug datarminad by l	Al mothod		
recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	LIIdotoxIII Levet	~1 LO/μg, determined by i	LAL Method.		
recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).	Poconcititution	It is not recommended to	roconstituto to a consontrat	tion loss than 100 ug/ml in s	IdH. O. For long torm storage it is
	Reconstitution				
Storage & Stability Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is		recommended to add a Ca	imer protein (0.1% boa, 5%	113A, 1070 FD3 01 370 Hellali	J3C/.
Storage & Stability Storied at -20 C for 2 years. After reconstitution, it is stable at 4 C for 1 week or -20 C for longer (with Carrier protein). It is	Storago & Stability	Stored at 20°C for 2 veges	After reconstitution it is at	able at 4°C for 1 week ar 20	°C for langer (with carrier protein). It is
	Storage & Stability	Stored at -20 Citor 2 years	. Arter reconstitution, it is st	able at 4 Cibi 1 Week of -20	C for longer (with carrier protein). It is

Page 1 of 2

	recommended to freeze aliquots at -20°C or -80°C for extended storage.
Shipping	Room temperature in continental US; may vary elsewhere.

### **DESCRIPTION**

#### Background

EGF Receptor (EGFR, ErbB1) is a transmembrane protein that exerts tyrosine kinase activity upon ligand induced activation. EGFR can be activated by binding EGF or at least six other structurally related protein ligands, including TGF $\alpha$ , HB-EGF, Betacellulin (BTC), Amphiregulin, Epiregulin, and Epigen. Upon activation, EGFR initiates a signaling cascade which includes dimerization and internalization, tyrosine phosphorylation, DNA synthesis of target genes, and, ultimately, cell proliferation. EGFR signaling plays a role in the growth and differentiation of normal cells, but elevated EGFR activity is correlated with the development and pathogenesis of certain cancers<sup>[1]</sup>.

#### **REFERENCES**

[1]. Scaltriti M, et al. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006 Sep 15;12(18):5268-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA